Clinical Trials Directory

Trials / Completed

CompletedNCT02168309

Oral Nifedipine Versus Oral Labetalol

Comparison of Oral Nifedipine to Oral Labetolol for the Management of Severe Postpartum Hypertension

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
50 (actual)
Sponsor
Cedars-Sinai Medical Center · Academic / Other
Sex
Female
Age
18 Years – 100 Years
Healthy volunteers
Not accepted

Summary

This study's aim is to determine whether oral extended release nifedipine is superior to oral labetolol for the management of postpartum severe hypertension, specifically time to achieve goal blood pressure, and shortening hospital stay. Our hypothesis is that oral extended release nifedipine is superior to oral labetolol for achieving goal blood pressure in the postpartum period.

Detailed description

Hypertension complicating pregnancy is common and, when uncontrolled, can have devastating consequences. While the true incidence of postpartum hypertension is unknown, blood pressure (BP) is known to initially decrease 48 hours following delivery then peak on postpartum days 3-6, likely 45 from the mobilization of interstitial fluids following parturition. The American College of Obstetricians and Gynecologists (ACOG) recommends medical treatment of persistent postpartum hypertension, defined as systolic BP (SBP) ≥150 mmHg or diastolic BP (DBP) ≥100 mmHg, on two or more occasions 4-6 hours apart. Prior studies compared intravenous medications to intramuscular and immediate-release oral 50 medications in the treatment of postpartum hypertension. However, oral labetalol and oral extended release nifedipine are the most commonly used medications for post- partum hypertension, and their efficacy has not been directly compared. Our aim was to determine whether oral labetalol is associated with a shorter time to BP control compared to oral extended release nifedipine for management of persistent 55 postpartum hypertension. Our primary outcome was time to sustained BP control defined as the absence of severe hypertension (SBP ≥160 mmHg or DBP ≥105 mmHg) for at least 12 hours. Secondary outcomes included postpartum length of stay, need for increased dosing, need for additional oral antihypertensive agents, and patient-reported side effects.

Conditions

Interventions

TypeNameDescription
DRUGLabetalolTitrate up for blood pressure control
DRUGNifedipineTitrate up to achieve blood pressure control

Timeline

Start date
2014-06-01
Primary completion
2015-06-01
Completion
2016-05-01
First posted
2014-06-20
Last updated
2017-12-13
Results posted
2017-12-13

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02168309. Inclusion in this directory is not an endorsement.